Recurrent and/or refractory (R/R) pediatric acute myeloid leukemia (AML) remains a
recalcitrant disease with poor outcomes. Cell therapy with genetically modified immune …

Chimeric antigen receptor (CAR) T cells are “living drugs” that specifically recognize their
target antigen through an antibody-derived binding domain resulting in T cell activation …

While cancer research and care have benefited from revolutionary advances in the ability to
manipulate and study living systems, the field is limited by a lack of synergy to leverage the …

The emergence of immune escape is a significant roadblock to developing effective chimeric
antigen receptor (CAR) T cell therapies against hematological malignancies, including acute …

Multiple chimeric antigen receptor (CAR) T cell therapies are FDA approved, and several
are under development. While effective for some cancers, toxicities remain a limitation. The …

Despite advancements, acute myeloid leukemia (AML) remains unconquered by current
therapies. Evidence of immune evasion during AML progression, such as HLA loss and T …

Engineering immune cells to treat hematological malignancies has been a major focus of
research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several …

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a poor
prognosis despite the advent of novel therapies. Consequently, a major need exists for new …

Chimeric antigen receptor (CAR) T cell therapies are limited by antigen escape and on-
target/off-tumor toxicity. In addressing these challenges, Haubner et al. develop an" IF …

Despite several small-molecule drugs that have revolutionized the current treatment strategy
for acute myeloid leukemia (AML), hematopoietic stem cell transplantation remains the only …